Axsome Therapeutics, Inc. (FRA:19X)

Revenue by Product

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Novel Therapies for the Management of Central Nervous System Disorders	385.69M
Novel Therapies for the Management of Central Nervous System Disorders Growth	42.53%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
United States	378.16M
United States Growth	91.74%
Non-United States	7.53M
Non-United States Growth	-89.73%